GLP-1 Dose Adjustment Guide

GLP-1 medications require a structured dose titration approach — starting at sub-therapeutic doses to minimize gastrointestinal side effects, then escalating every 4 weeks to the target maintenance dose.

Semaglutide (Ozempic/Wegovy) starts at 0.25 mg weekly and escalates to 2.4 mg over 16–20 weeks. Tirzepatide (Mounjaro/Zepbound) starts at 2.5 mg and escalates to 15 mg over 20 weeks. Knowing when to delay escalation, hold a dose, or step down due to side effects is essential for tolerability and long-term adherence.

Week Semaglutide (Wegovy) Semaglutide (Ozempic T2D) Tirzepatide

The standard 4-week escalation schedule is a guideline, not a rigid requirement. Slowing dose escalation is appropriate — and evidence-supported — when GI side effects are limiting quality of life or causing dehydration/significant weight loss from vomiting.

Signs that warrant staying at the current dose for an additional 4 weeks: persistent nausea rating ≥4/10 on most days of the week, any vomiting beyond occasional episodes after meals, diarrhea more than 3x/day interfering with daily activities, or any dehydration symptoms (dizziness, urine).

The therapeutic goal is to reach the highest tolerated dose, not the highest possible dose on the fastest schedule. Clinical data confirm that even lower maintenance doses (semaglutide 1 mg, tirzepatide 10 mg) produce significant weight loss and glycemic benefits — reaching maximum dose at any cost is not necessary for clinical success.

Communicate side effects to your prescribing physician before dose escalation days.

Dose reduction (stepping down to the previous dose level) is indicated when: current dose causes intolerable GI side effects that have persisted beyond 4 weeks at that dose level, patient develops significant nausea preventing adequate nutrition or hydration, or vomiting becomes frequent.

Dose holding (temporarily stopping) is appropriate when: surgical procedure is planned within 1–4 weeks (anesthesia aspiration risk), significant acute illness causing dehydration (vomiting/diarrhea), or acute pancreatitis is suspected.

Do not permanently stop GLP-1 therapy without discussing with your physician — abrupt discontinuation is followed by return of appetite and weight regain, often at an accelerated rate (rebound appetite).

After resolving the issue that required holding, restart at the lower dose step and re-escalate more slowly. For patients who tolerated a lower dose but not a higher one, indefinite maintenance at the lower tolerated dose is a valid long-term strategy endorsed by clinical guidelines.

The FDA-approved titration schedule for semaglutide (Wegovy) increases the dose every 4 weeks: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg (maintenance).

This 16–20 week escalation is designed to minimize GI side effects by allowing the gut to adapt to GLP-1 receptor activation at each dose level. However, this schedule can and should be modified based on individual tolerance.

If nausea is significant at any step, spend an additional 4–8 weeks at that dose before escalating. There is no clinical requirement to reach 2.4 mg — lower doses (1.0–1.7 mg) still produce clinically significant weight loss and glycemic improvement.

Some physicians use extended titration protocols over 6–12 months for highly sensitive patients, achieving better long-term adherence than rapid escalation with poor tolerance. Use Shotlee to track your dose history, side effect severity, and weekly weight to help your physician make informed titration decisions.

Missing a single weekly GLP-1 injection occasionally is not cause for alarm and does not require a compensatory double dose.

For semaglutide (weekly): if the missed dose is within 5 days of the scheduled day, inject as soon as you remember. If more than 5 days have passed, skip that week's dose and resume on the regular schedule the following week.

For tirzepatide (weekly): same protocol — if within 4 days, take as soon as possible; if more than 4 days, skip and resume the next scheduled day. Important: do not double-dose to compensate for a missed injection — doubling can cause severe GI side effects.

After an extended break (more than 2 weeks), some patients experience return of GI side effects upon restarting, similar to dose escalation. If you've been off for more than 2 weeks, discuss with your physician whether to restart at a lower dose and re-escalate before returning to your previous maintenance dose.

Yes — remaining on a lower maintenance dose of semaglutide is a clinically valid long-term strategy if higher doses are not tolerated.

Many patients achieve meaningful and sustained weight loss and glycemic improvement at doses below the maximum approved dose. In STEP trials, semaglutide 1.0 mg weekly (approved for T2D as Ozempic) produced approximately 6–8% body weight reduction — significant and clinically meaningful even if less than the 15% seen with 2.4 mg.

Similarly, tirzepatide 10 mg produces approximately 19% weight loss vs 22% with 15 mg — the lower dose is still highly effective. The dose is a tool to optimize outcomes, not an end goal in itself. If side effects at higher doses significantly impact quality of life, maintaining indefinitely at the highest well-tolerated dose provides meaningful benefit.

Always make dose decisions collaboratively with your prescribing physician rather than without guidance.